Abstract
Optimal renin-angiotensin-aldosterone system inhibitors (RAASi) therapy has demonstrated to delay progression of chronic kidney disease (CKD), heart failure (HF) and hypertension. However, RAASi therapy is associated with an increased risk of hyperkalaemia (HK), leading to dose reduction or discontinuation of therapy and shortening its potential cardio-renal benefits. Patiromer is a novel therapy for HK treatment that maintains normokalaemia and also enables to maintain RAASi therapy. This study aimed to assess the cost-effectiveness of patiromer versus no patiromer for the management of HK in patients with CKD with or without HF from the Spanish healthcare perspective.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
